Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.
MER Indicator |
MER description |
Target Fiscal Year |
Target |
BS_COLL |
By: Number of whole blood donations screened for HIV in an NBTS ne2rk laboratory |
2015 |
191,700 |
BS_COLL |
By: Number of whole blood donations screened for HIV in an NBTS ne2rk laboratory that are identified as reactive for HIV |
2015 |
4,260 |
BS_COLL |
Number of whole blood collections each year by the NBTS ne2rk |
2015 |
213,000 |
GEND_GBV |
Age: 0-9 |
2015 |
42 |
GEND_GBV |
Age: 10-14 |
2015 |
86 |
GEND_GBV |
Age: 15-17 |
2015 |
127 |
GEND_GBV |
Age: 18-24 |
2015 |
75 |
GEND_GBV |
Age: 25+ |
2015 |
37 |
GEND_GBV |
By PEP service provision (related to sexual violence services provided) |
2015 |
285 |
GEND_GBV |
By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) |
2015 |
82 |
GEND_GBV |
By type of service: Sexual Violence (Post-Rape Care) |
2015 |
285 |
GEND_GBV |
Number of people receiving post-GBV care |
2015 |
367 |
GEND_GBV |
Sex: Female |
2015 |
245 |
GEND_GBV |
Sex: Male |
2015 |
122 |
GEND_GBV |
Sum of Age disaggregates |
2015 |
367 |
GEND_GBV |
Sum of Sex disaggregates |
2015 |
367 |
HTS_TST |
Age/sex: <1 Female |
2015 |
5,852 |
HTS_TST |
Age/sex: <1 Female |
2015 |
5,852 |
HTS_TST |
Age/sex: <1 Male |
2015 |
5,622 |
HTS_TST |
Age/sex: <1 Male |
2015 |
5,622 |
HTS_TST |
Age/sex: 1-4 Female |
2015 |
3,570 |
HTS_TST |
Age/sex: 1-4 Female |
2015 |
3,570 |
HTS_TST |
Age/sex: 1-4 Male |
2015 |
3,408 |
HTS_TST |
Age/sex: 1-4 Male |
2015 |
3,407 |
HTS_TST |
Age/sex: 10-14 Female |
2015 |
3,165 |
HTS_TST |
Age/sex: 10-14 Female |
2015 |
3,165 |
HTS_TST |
Age/sex: 10-14 Male |
2015 |
3,083 |
HTS_TST |
Age/sex: 10-14 Male |
2015 |
3,083 |
HTS_TST |
Age/sex: 15-19 Female |
2015 |
75,689 |
HTS_TST |
Age/sex: 15-19 Female |
2015 |
75,689 |
HTS_TST |
Age/sex: 15-19 Male |
2015 |
34,201 |
HTS_TST |
Age/sex: 15-19 Male |
2015 |
34,201 |
HTS_TST |
Age/sex: 20-24 Female |
2015 |
213,914 |
HTS_TST |
Age/sex: 20-24 Female |
2015 |
213,914 |
HTS_TST |
Age/sex: 20-24 Male |
2015 |
70,795 |
HTS_TST |
Age/sex: 20-24 Male |
2015 |
70,795 |
HTS_TST |
Age/sex: 25-49 Female |
2015 |
451,787 |
HTS_TST |
Age/sex: 25-49 Female |
2015 |
451,786 |
HTS_TST |
Age/sex: 25-49 Male |
2015 |
222,405 |
HTS_TST |
Age/sex: 25-49 Male |
2015 |
222,405 |
HTS_TST |
Age/sex: 5-9 Female |
2015 |
1,420 |
HTS_TST |
Age/sex: 5-9 Female |
2015 |
1,420 |
HTS_TST |
Age/sex: 5-9 Male |
2015 |
1,379 |
HTS_TST |
Age/sex: 5-9 Male |
2015 |
1,379 |
HTS_TST |
Age/sex: 50+ Female |
2015 |
7,100 |
HTS_TST |
Age/sex: 50+ Female |
2015 |
7,100 |
HTS_TST |
Age/sex: 50+ Male |
2015 |
6,897 |
HTS_TST |
Age/sex: 50+ Male |
2015 |
6,897 |
HTS_TST |
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female |
2015 |
14,006 |
HTS_TST |
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male |
2015 |
13,493 |
HTS_TST |
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female |
2015 |
748,490 |
HTS_TST |
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male |
2015 |
334,297 |
HTS_TST |
Aggregated Age/sex: <15 Female |
2015 |
14,006 |
HTS_TST |
Aggregated Age/sex: <15 Male |
2015 |
13,493 |
HTS_TST |
Aggregated Age/sex: 15+ Female |
2015 |
748,490 |
HTS_TST |
Aggregated Age/sex: 15+ Male |
2015 |
334,297 |
HTS_TST |
By Test Result: Negative |
2015 |
1,081,777 |
HTS_TST |
By Test Result: Negative |
2015 |
1,081,777 |
HTS_TST |
Number of individuals who received T&C services for HIV and received their test results during the past 12 months |
2015 |
1,110,286 |
HTS_TST |
Number of individuals who received T&C services for HIV and received their test results during the past 12 months |
2015 |
1,110,286 |
HTS_TST |
Sum of Age/Sex disaggregates |
2015 |
1,110,286 |
HTS_TST |
Sum of Age/Sex disaggregates |
2015 |
1,110,286 |
HTS_TST |
Sum of Aggregated Age/Sex <15 |
2015 |
27,499 |
HTS_TST |
Sum of Aggregated Age/Sex <15 |
2015 |
27,499 |
HTS_TST |
Sum of Aggregated Age/Sex 15+ |
2015 |
1,082,787 |
HTS_TST |
Sum of Aggregated Age/Sex 15+ |
2015 |
1,082,787 |
HTS_TST |
Sum of Aggregated Age/Sex disaggregates |
2015 |
1,110,286 |
HTS_TST |
Sum of Aggregated Age/Sex disaggregates |
2015 |
1,110,286 |
HTS_TST |
Sum of Test Result disaggregates |
2015 |
1,110,286 |
HTS_TST |
Sum of Test Result disaggregates |
2015 |
1,110,286 |
HTS_TST_POS |
By Test Result: Positive |
2015 |
28,509 |
HTS_TST_POS |
By Test Result: Positive |
2015 |
28,509 |
LAB_ACC |
By site support type: Direct Service Delivery (DSD) |
2015 |
10 |
LAB_ACC |
Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation |
2015 |
10 |
LAB_ACC |
Sum of Support Type disaggregates |
2015 |
10 |
LAB_CAP |
By clinical laboratories |
2015 |
94 |
LAB_CAP |
By site support type: Direct Service Delivery (DSD) |
2015 |
94 |
LAB_CAP |
Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests |
2015 |
94 |
LAB_CAP |
Sum of Site Support Type disaggregates |
2015 |
94 |
OVC_ACC |
Age: <1 |
2015 |
1,460 |
OVC_ACC |
Age: 1-4 |
2015 |
6,083 |
OVC_ACC |
Age: 10-14 |
2015 |
5,840 |
OVC_ACC |
Age: 15-17 |
2015 |
3,407 |
OVC_ACC |
Age: 18+ |
2015 |
730 |
OVC_ACC |
Age: 5-9 |
2015 |
6,813 |
OVC_ACC |
Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services |
2015 |
24,333 |
OVC_ACC |
Sex: Female |
2015 |
12,410 |
OVC_ACC |
Sex: Male |
2015 |
11,923 |
OVC_ACC |
Sum of Age disaggregates |
2015 |
24,333 |
OVC_ACC |
Sum of Sex disaggregates |
2015 |
24,333 |
OVC_SERV |
Age: <1 |
2015 |
4,867 |
OVC_SERV |
Age: 1-4 |
2015 |
20,277 |
OVC_SERV |
Age: 10-14 |
2015 |
19,466 |
OVC_SERV |
Age: 15-17 |
2015 |
11,355 |
OVC_SERV |
Age: 18+ |
2015 |
2,433 |
OVC_SERV |
Age: 5-9 |
2015 |
22,711 |
OVC_SERV |
Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS |
2015 |
81,109 |
OVC_SERV |
Sex: Female |
2015 |
41,366 |
OVC_SERV |
Sex: Male |
2015 |
39,743 |
OVC_SERV |
Sum of Age disaggregates |
2015 |
81,109 |
OVC_SERV |
Sum of Sex disaggregates |
2015 |
81,109 |
PMTCT_ARV |
Life-long ART (including Option B+) |
2015 |
6,311 |
PMTCT_ARV |
Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery) |
2015 |
573 |
PMTCT_ARV |
Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period) |
2015 |
4,590 |
PMTCT_ARV |
Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) |
2015 |
12,609 |
PMTCT_ARV |
Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery |
2015 |
11,474 |
PMTCT_ARV |
Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy |
2015 |
4,172 |
PMTCT_ARV |
Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy |
2015 |
2,138 |
PMTCT_ARV |
Sum of New and Current disaggregates |
2015 |
6,310 |
PMTCT_ARV |
Sum of Regimen Type disaggregates |
2015 |
11,474 |
PMTCT_ARV_NGI |
Life-long ART (including Option B+) |
2015 |
6,311 |
PMTCT_ARV_NGI |
Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery) |
2015 |
573 |
PMTCT_ARV_NGI |
Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period) |
2015 |
4,590 |
PMTCT_ARV_NGI |
Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) |
2015 |
12,609 |
PMTCT_ARV_NGI |
Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery |
2015 |
11,474 |
PMTCT_ARV_NGI |
Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy |
2015 |
4,172 |
PMTCT_ARV_NGI |
Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy |
2015 |
2,138 |
PMTCT_ARV_NGI |
Sum of New and Current disaggregates |
2015 |
6,310 |
PMTCT_ARV_NGI |
Sum of Regimen disaggregates |
2015 |
11,474 |
PMTCT_EID |
By infants who received a virologic test within 2 months of birth |
2015 |
3,786 |
PMTCT_EID |
By infants who received their first virologic HIV test between 2 and 12 months of age |
2015 |
7,688 |
PMTCT_EID |
By infants with a positive virologic test result within 12 months of birth |
2015 |
574 |
PMTCT_EID |
Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT) |
2015 |
13,284 |
PMTCT_EID |
Number of infants who had a virologic HIV test within 12 months of birth during the reporting period |
2015 |
11,474 |
PMTCT_EID |
Sum of Infant Age disaggregates |
2015 |
11,474 |
PMTCT_STAT |
By: Known positives at entry |
2015 |
5,044 |
PMTCT_STAT |
By: Number of new positives identified |
2015 |
7,565 |
PMTCT_STAT |
Number of new ANC and L&D clients |
2015 |
445,854 |
PMTCT_STAT |
Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) |
2015 |
405,727 |
PMTCT_STAT |
Sum of Positives Status disaggregates |
2015 |
12,609 |
PMTCT_STAT_NGI |
By: Known positives at entry |
2015 |
5,044 |
PMTCT_STAT_NGI |
By: Number of new positives identified |
2015 |
7,565 |
PMTCT_STAT_NGI |
Number of new ANC and L&D clients |
2015 |
445,854 |
PMTCT_STAT_NGI |
Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) |
2015 |
405,727 |
PMTCT_STAT_NGI |
Sum of Positives Status disaggregates |
2015 |
12,609 |
PP_PREV |
Age/sex: 10-14 Female |
2015 |
2,927 |
PP_PREV |
Age/sex: 10-14 Male |
2015 |
2,812 |
PP_PREV |
Age/sex: 15-19 Female |
2015 |
3,512 |
PP_PREV |
Age/sex: 15-19 Male |
2015 |
3,374 |
PP_PREV |
Age/sex: 20-24 Female |
2015 |
8,781 |
PP_PREV |
Age/sex: 20-24 Male |
2015 |
8,436 |
PP_PREV |
Age/sex: 25-49 Female |
2015 |
13,171 |
PP_PREV |
Age/sex: 25-49 Male |
2015 |
12,655 |
PP_PREV |
Age/sex: 50+ Female |
2015 |
878 |
PP_PREV |
Age/sex: 50+ Male |
2015 |
844 |
PP_PREV |
Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period |
2015 |
57,390 |
PP_PREV |
Sum of Age/Sex disaggregates |
2015 |
57,390 |
PP_PREV |
Total number of people in the target population |
2015 |
208,503 |
QI_SITE |
By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months |
2015 |
156 |
QI_SITE |
By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, HTC |
2015 |
204 |
QI_SITE |
Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months |
2015 |
156 |
QI_SITE |
Sum of Numerator Site Support Type disaggregates |
2015 |
156 |
QI_SITE |
Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC |
2015 |
204 |
QI_SITE_den |
Sum of Denominator Site Support Type disaggregates |
2015 |
204 |
TB_ART |
Age: 0-4 |
2015 |
48 |
TB_ART |
Age: 15+ |
2015 |
4,506 |
TB_ART |
Age: 5-14 |
2015 |
240 |
TB_ART |
Aggregated Age: <15 |
2015 |
288 |
TB_ART |
Aggregated Age: 15+ |
2015 |
4,506 |
TB_ART |
Female |
2015 |
2,445 |
TB_ART |
Known HIV-positive |
2015 |
2,061 |
TB_ART |
Male |
2015 |
2,349 |
TB_ART |
Newly tested |
2015 |
2,733 |
TB_ART |
Sum of Aggregated Age disaggregates |
2015 |
4,794 |
TB_ART |
Sum of Sex disaggregates |
2015 |
4,794 |
TB_ART |
Sum of Test Status disaggregates |
2015 |
4,794 |
TB_ART |
The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period |
2015 |
4,794 |
TB_ART |
The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period |
2015 |
4,794 |
TB_SCREEN |
Age: <1 |
2015 |
2,841 |
TB_SCREEN |
Age: 1-4 |
2015 |
1,420 |
TB_SCREEN |
Age: 10-14 |
2015 |
1,420 |
TB_SCREEN |
Age: 15-19 |
2015 |
14,204 |
TB_SCREEN |
Age: 20-24 |
2015 |
35,509 |
TB_SCREEN |
Age: 25-49 |
2015 |
78,120 |
TB_SCREEN |
Age: 5-9 |
2015 |
2,841 |
TB_SCREEN |
Age: 50+ |
2015 |
5,681 |
TB_SCREEN |
Aggregated Age - USE WITH HQ PERMISSION ONLY: <15 |
2015 |
8,522 |
TB_SCREEN |
Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+ |
2015 |
133,514 |
TB_SCREEN |
Sex: Female |
2015 |
99,425 |
TB_SCREEN |
Sex: Male |
2015 |
42,611 |
TB_SCREEN |
Sum of Age disaggregates |
2015 |
22,726 |
TB_SCREEN |
Sum of Aggregated Age disaggregates |
2015 |
142,036 |
TB_SCREEN |
Sum of Sex disaggregates |
2015 |
142,036 |
TB_SCREEN |
The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period |
2015 |
142,036 |
TX_CURR |
Age/Sex: <1 Female |
2015 |
181 |
TX_CURR |
Age/Sex: <1 Male |
2015 |
204 |
TX_CURR |
Age/Sex: 1-4 Female |
2015 |
851 |
TX_CURR |
Age/Sex: 1-4 Male |
2015 |
960 |
TX_CURR |
Age/Sex: 15+ Female |
2015 |
65,315 |
TX_CURR |
Age/Sex: 15+ Male |
2015 |
32,171 |
TX_CURR |
Age/Sex: 5-14 Female |
2015 |
1,548 |
TX_CURR |
Age/Sex: 5-14 Male |
2015 |
1,746 |
TX_CURR |
Aggregated Age/Sex: <1 Female |
2015 |
181 |
TX_CURR |
Aggregated Age/Sex: <1 Male |
2015 |
204 |
TX_CURR |
Aggregated Age/Sex: <15 Female |
2015 |
2,580 |
TX_CURR |
Aggregated Age/Sex: <15 Male |
2015 |
2,909 |
TX_CURR |
Aggregated Age/Sex: 15+ Female |
2015 |
65,316 |
TX_CURR |
Aggregated Age/Sex: 15+ Male |
2015 |
32,171 |
TX_CURR |
Number of adults and children receiving antiretroviral therapy (ART) |
2015 |
102,976 |
TX_CURR |
Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT] |
2015 |
5 |
TX_CURR |
Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT] |
2015 |
66 |
TX_CURR |
Sum of age/sex disaggregates |
2015 |
5,490 |
TX_CURR |
Sum of Aggregated Age/Sex <15 |
2015 |
5,489 |
TX_CURR |
Sum of Aggregated Age/Sex 15+ |
2015 |
97,487 |
TX_CURR |
Sum of Aggregated Age/Sex disaggregates |
2015 |
102,976 |
TX_CURR_NGI |
Age/Sex: <1 Female |
2015 |
181 |
TX_CURR_NGI |
Age/Sex: <1 Male |
2015 |
204 |
TX_CURR_NGI |
Age/Sex: 1-4 Female |
2015 |
851 |
TX_CURR_NGI |
Age/Sex: 1-4 Male |
2015 |
960 |
TX_CURR_NGI |
Age/Sex: 15+ Female |
2015 |
65,316 |
TX_CURR_NGI |
Age/Sex: 15+ Male |
2015 |
32,171 |
TX_CURR_NGI |
Age/Sex: 5-14 Female |
2015 |
1,546 |
TX_CURR_NGI |
Age/Sex: 5-14 Male |
2015 |
1,746 |
TX_CURR_NGI |
Aggregated Age/Sex: <1 Female |
2015 |
181 |
TX_CURR_NGI |
Aggregated Age/Sex: <1 Male |
2015 |
204 |
TX_CURR_NGI |
Aggregated Age/Sex: <15 Female |
2015 |
2,580 |
TX_CURR_NGI |
Aggregated Age/Sex: <15 Male |
2015 |
2,909 |
TX_CURR_NGI |
Aggregated Age/Sex: 15+ Female |
2015 |
65,316 |
TX_CURR_NGI |
Aggregated Age/Sex: 15+ Male |
2015 |
32,170 |
TX_CURR_NGI |
Number of adults and children receiving antiretroviral therapy (ART) |
2015 |
102,975 |
TX_CURR_NGI |
Sum of Age/Sex disaggregates |
2015 |
102,975 |
TX_CURR_NGI |
Sum of Aggregated Age/Sex <15 |
2015 |
5,489 |
TX_CURR_NGI |
Sum of Aggregated Age/Sex 15+ |
2015 |
97,486 |
TX_CURR_NGI |
Sum of Aggregated Age/Sex disaggregates |
2015 |
102,975 |
TX_NEW |
Aggregated Grouping by Age: <1 Male |
2015 |
222 |
TX_NEW |
Aggregated Grouping by Age/Sex: <1 Female |
2015 |
518 |
TX_NEW |
Aggregated Grouping by Age/Sex: <15 Female |
2015 |
1,185 |
TX_NEW |
Aggregated Grouping by Age/Sex: <15 Male |
2015 |
508 |
TX_NEW |
Aggregated Grouping by Age/Sex: 15+ Female |
2015 |
21,050 |
TX_NEW |
Aggregated Grouping by Age/Sex: 15+ Male |
2015 |
9,022 |
TX_NEW |
Breastfeeding status |
2015 |
1,053 |
TX_NEW |
By Age/Sex: <1 Female |
2015 |
518 |
TX_NEW |
By Age/Sex: <1 Male |
2015 |
222 |
TX_NEW |
By Age/Sex: 1-4 Female |
2015 |
378 |
TX_NEW |
By Age/Sex: 1-4 Male |
2015 |
162 |
TX_NEW |
By Age/Sex: 10-14 Female |
2015 |
111 |
TX_NEW |
By Age/Sex: 10-14 Male |
2015 |
48 |
TX_NEW |
By Age/Sex: 15-19 Female |
2015 |
2,224 |
TX_NEW |
By Age/Sex: 15-19 Male |
2015 |
953 |
TX_NEW |
By Age/Sex: 20-24 Female |
2015 |
3,335 |
TX_NEW |
By Age/Sex: 20-24 Male |
2015 |
1,429 |
TX_NEW |
By Age/Sex: 25-49 Female |
2015 |
14,454 |
TX_NEW |
By Age/Sex: 25-49 Male |
2015 |
6,194 |
TX_NEW |
By Age/Sex: 5-9 Female |
2015 |
178 |
TX_NEW |
By Age/Sex: 5-9 Male |
2015 |
76 |
TX_NEW |
By Age/Sex: 50+ Female |
2015 |
1,038 |
TX_NEW |
By Age/Sex: 50+ Male |
2015 |
445 |
TX_NEW |
Number of adults and children newly enrolled on antiretroviral therapy (ART) |
2015 |
31,765 |
TX_NEW |
Pregnancy status |
2015 |
2,105 |
TX_NEW |
Sum of Age/Sex disaggregates |
2015 |
31,765 |
TX_NEW |
Sum of Aggregated Age/Sex disaggregates |
2015 |
31,765 |
TX_RET |
Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) |
2015 |
549 |
TX_RET |
Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) |
2015 |
26,061 |
TX_RET |
Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) |
2015 |
823 |
TX_RET |
Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) |
2015 |
1,372 |
TX_RET |
Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) |
2015 |
26,061 |
TX_RET |
Number of adults and children who are still alive and on treatment at 12 months after initiating ART |
2015 |
27,433 |
TX_RET |
Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) |
2015 |
12,893 |
TX_RET |
Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up |
2015 |
32,274 |
TX_RET_den |
Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) |
2015 |
645 |
TX_RET_den |
Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) |
2015 |
30,660 |
TX_RET_den |
Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) |
2015 |
968 |
TX_RET_den |
Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) |
2015 |
1,614 |
TX_RET_den |
Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) |
2015 |
30,660 |
TX_RET_den |
Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) |
2015 |
1,517 |